Public health vaccination policies for containing an anthrax outbreak

Nature

Volumn 432, Issue 7019, 2004, Pages 901-904

  Brookmeyer, Ron ^a   Johnson, Elizabeth ^a   Bollinger, Robert ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; PREVENTION; PROBABILITY; PUBLIC POLICY; VACCINES;

ANTHRAX; POST-EXPOSURE VACCINATION; PUBLIC HEALTH POLICIES;

HEALTH CARE;

ANTHRAX VACCINE; ANTIBIOTIC AGENT;

MEDICINE;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL SPORE; EPIDEMIC; HEALTH CARE POLICY; HEALTH PROGRAM; IMMUNITY; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH; SPORE GERMINATION; STATISTICAL MODEL; VACCINATION;

ANTHRAX; ANTHRAX VACCINES; ANTIBIOTIC PROPHYLAXIS; DISASTER PLANNING; DISEASE OUTBREAKS; HUMANS; MASS IMMUNIZATION; MODELS, BIOLOGICAL; PROBABILITY; PUBLIC HEALTH; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

ANTHRAX; BACTERIA (MICROORGANISMS); POSIBACTERIA;

EID: 11144336587     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03087     Document Type: Article

References (28)

1. Inglesby, T. V. et al. Anthrax as a biological weapon: medical and public health management. J. Am. Med. Assoc. 281, 1735-1745 (1999).
2. Inglesby, T. V. et al. Anthrax as a biological weapon. Updated recommendations for management. J. Am. Med. Assoc. 287, 2236-2252 (2002).
3. Centers for Disease Control. Notice to readers: use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. Morb. Mortal. Wkly Rep. 51, 1024-1026 (2002).
4. Jernigan, J. A. et al. Bioterrorism-related inhalation anthrax: The first 10 cases reported in the United States. Emerg. Infect. Dis. 17, 933-944 (2001).
5. Joellenbeck, L., Zwanziger, L., Durch, J. & Strom, B. (eds) The Anthrax Vaccine: Is it Safe? Does it Work? (National Academy Press, Washington DC, 2002).
6. National Institute of Allergy and Infectious Diseases. National Institute of Allergy and Infectious Diseases biodefense research agenda for CDC category A agents. 〈http://www.niaid.nih.gov/publications/bioterrorism.htm〉 (2002).
7. Centers for Disease Control. Update: investigation of bioterrorism-related anthrax. Morb. Mortal. Wkly Rep. 50, 1008-1010 (2001).
8. Shepard, C. W. et al. Antimicrobial post-exposure prophylaxis for anthrax: Adverse events and adherence. Emerg. Infect Dis. 8, 1124-1132 (2002).
9. Brookmeyer, R. & Blades, N. Prevention of inhalational anthrax in the U.S. outbreak. Science 295, 1861 (2002).
10. Meselson, M. et al. The Sverdlovsk anthrax outbreak of 1979. Science 266, 1202-1208 (1994).
11. Wein, L. M., Craft, D. L. & Kaplan, E. H. Emergency response to an anthrax outbreak. Proc. Natl Acad. Sci. USA 100, 4346-4351 (2003).
12. Committee on Research and Development Needs fot Improving Civilian Medical Response to Chemical and Biological Terrorism Incidents. Chemical and Biological Terrorism (National Academy Press, Washington DC, 1999).
13. Kaplan, E. H., Craft, D. L. & Wein, L. M. Emergency response to a smallpox attack: the case for mass vaccination. Proc. Natl Acad. Sci. USA 99, 10935-10940 (2002).
14. Bozette, S. et al. A model for a smallpox-vaccination policy. N. Engl. J. Med. 348, 416-425 (2003).
15. Halloran, M. E., Longini, I. M. Jr, Nizam, A. & Yang, Y. Containing bioterrorist smallpox. Science 298, 1428-1432 (2002).
16. Ferguson, N. M. et al. Planning for smallpox outbreak. Nature 425, 681-685 (2003).
17. Fraser, C., Riley, S., Anderson, R. M. & Ferguson, N. M. Factors that make an infectious disease outbreak controllable. Proc. Natl. Acad. Sci. USA 101, 6146-6151 (2004).
18. Kaufmann, A., Meltzer, M. & Schmid, G. The economic impact of a bioterrorist attack: Are prevention and post attack intervention programs justifiable? Emerg. Infect. Dis. 3, 83-94 (1997).
19. Centers for Disease Control and Prevention. Mass antibiotic dispensing: A primer. 〈http://www.phppo.cdc.gov/phtn/antibiotic/default.asp〉 (June 2004).
20. Brookmeyer, R., Johnson, E. & Bollinger, R. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc. Natl. Acad. Sci. USA 100, 10129-10132 (2003).
21. Brachman, P. S. Inhalation anthrax. Ann. NY Acad. Sci. 353, 83-93 (1980).
22. Ross, J. M. The pathogenesis of anthrax following the administration of spores by the respiratory route. J. Pathol. Bacteriol. 73, 484-494 (1957).
23. Friedlander, A. M. et al. Post-exposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167, 1239-1242 (1993).
24. Friedlander, A. M. Anthrax: clinical features, pathogenesis and potential biological warfare threat. Curr. Clin. Top. Infect Dis. 20, 335-349 (2000).
25. Cieslak, T. J. & Edward, M. E. Clinical and epidemiological principles of anthrax. Infect. Dis. 5, 51-55 (1999).
26. Henderson, D. W., Peakcock, S. & Belton, F. C. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J. Hyg. (Lond.) 54, 28-35 (1956).
27. Haas, C. N. On the risk of mortality to primates exposed to anthrax spores. Risk Anal. 22, 189-193 (2002).
28. Watson, A. & Keir, D. Information on which to base assessments of risk from environmental contaminated with anthrax spores. Epidemiol. Infect. 113, 479-490 (1994).